These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 17504999)
1. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999 [TBL] [Abstract][Full Text] [Related]
2. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887 [TBL] [Abstract][Full Text] [Related]
3. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Slovin SF; Ragupathi G; Fernandez C; Jefferson MP; Diani M; Wilton AS; Powell S; Spassova M; Reis C; Clausen H; Danishefsky S; Livingston P; Scher HI Vaccine; 2005 May; 23(24):3114-22. PubMed ID: 15837210 [TBL] [Abstract][Full Text] [Related]
4. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545 [TBL] [Abstract][Full Text] [Related]
5. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001 [TBL] [Abstract][Full Text] [Related]
6. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710 [TBL] [Abstract][Full Text] [Related]
7. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727 [TBL] [Abstract][Full Text] [Related]
10. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. MacLean GD; Reddish MA; Koganty RR; Longenecker BM J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725 [TBL] [Abstract][Full Text] [Related]
11. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946 [TBL] [Abstract][Full Text] [Related]
12. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies. Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435 [TBL] [Abstract][Full Text] [Related]
13. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361 [TBL] [Abstract][Full Text] [Related]
14. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403 [TBL] [Abstract][Full Text] [Related]
15. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527 [TBL] [Abstract][Full Text] [Related]
16. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144 [TBL] [Abstract][Full Text] [Related]
17. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472 [TBL] [Abstract][Full Text] [Related]
18. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Longenecker BM; Reddish M; Koganty R; MacLean GD Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. Eggermont AM; Suciu S; Rutkowski P; Marsden J; Santinami M; Corrie P; Aamdal S; Ascierto PA; Patel PM; Kruit WH; Bastholt L; Borgognoni L; Bernengo MG; Davidson N; Polders L; Praet M; Spatz A J Clin Oncol; 2013 Oct; 31(30):3831-7. PubMed ID: 24019551 [TBL] [Abstract][Full Text] [Related]